Edgewise Therapeutics
EWTX
225 hedge funds and large institutions have $4.82B invested in Edgewise Therapeutics in 2026 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 83 increasing their positions, 73 reducing their positions, and 26 closing their positions.
94% more call options, than puts
Call options by funds: $17.6M | Put options by funds: $9.08M
62% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 26
30% more capital invested
Capital invested by funds: $3.72B → $4.82B (+$1.1B)
18% more funds holding in top 10
Funds holding in top 10: 11 → 13 (+2)
14% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 73
5% more funds holding
Funds holding: 214 → 225 (+11)
0.28% more ownership
Funds ownership: 110.5% → 110.77% (+0.28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$154M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$98.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.8M |
| 4 |
TCM
Tyro Capital Management
Miami,
Florida
|
+$21.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$99.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$70.2M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$48.1M |
| 4 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$42.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$39.2M |
EWTX Hedge Fund Activity: Q2 2026 in Review
225 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q2 2026, worth a combined $4.82B — up 30% from $3.72B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new EWTX positions and 26 closed out — a net gain of 16 holders — while 83 added to existing stakes and 73 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $154M. The largest seller was Baker Bros. Advisors, cutting an estimated $99.1M.
- 225 institutional investors held Edgewise Therapeutics (EWTX) as of Q2 2026, up from 214 in Q1 2026.
- Funds reported $4.82B of Edgewise Therapeutics stock for Q2 2026, up 30% quarter-over-quarter.
- 42 funds opened new Edgewise Therapeutics positions in Q2 2026 and 26 closed out, a net change of +16 holders.
- The largest Edgewise Therapeutics buyer in Q2 2026 was Fidelity Investments, an estimated $154M added.
- The largest Edgewise Therapeutics seller in Q2 2026 was Baker Bros. Advisors, an estimated $99.1M sold.
Based on aggregated 13F filings for Q2 2026.